Brain Cancer Trial, Recruiting NCT06113705 Sponsor: Istituto Clinico Humanitas Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06113705
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any sex or racial background.
  • People who have been diagnosed with a specific type of brain tumour called glioblastoma multiforme (confirmed by tissue testing or by medical history, symptoms, and brain scan results that strongly point to this diagnosis).
  • People whose tumour has tested negative for a genetic change called an IDH1-2 mutation (this is a specific tumour characteristic that the trial site will assess).
  • People whose treating team has determined they are suitable to receive a standard combination of chemotherapy (called temozolomide) and radiation therapy.
  • People who are willing and able to give signed consent to take part in the trial.

Who may not be able to join:

  • People under 18 years of age.
  • People whose treating team has determined they are not suitable to receive the chemotherapy and radiation therapy combination used in this trial.
  • People who cannot safely have a contrast-enhanced MRI scan — for example, those with a pacemaker or a known allergy to the contrast dye used (gadolinium).
  • People who are HIV positive.
  • People who have other ongoing infection-related or inflammatory conditions affecting the body or brain, such as multiple sclerosis, lupus, Crohn's disease, or rheumatoid arthritis.
  • People who are currently pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Letterio S Politi, MD, Humanitas Research Hospital IRCCS, Rozzano-Milan

Phone: +390282245644

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istituto Clinico Humanitas
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Predictive models of pseudoprogression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov